Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.J. Pownall, C.M. Ballantyne, K.T. Kimball, S.L. Simpson, D. Yeshurun, A.M. Gotto Jr..
Effect of moderate alcohol consumption on hypertriglyceridemia.
Arch Intern Med, 159 (1999), pp. 981-987
[2.]
J. Rubiés-Prat.
Hiperlipoproteinemias secundarias.
Medicina interna Farreras-Rozman, pp. 2174-2179
[3.]
H.N. Ginsberg, I.J. Goldberg.
Disorders of lipoprotein metabolism.
Harrison’s principles of internal medicine, pp. 2245-2257
[4.]
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[5.]
J.L. Reverter, M. Sentí, J. Rubiés-Prat, A. Lucas, I. Salinas, E. Pizarro, et al.
Lipoprotein composition in the insulin-deficient nonacidotic phase of type I diabetic patients and early evolution after the start of insulin therapy.
Clin Chim Acta, 223 (1993), pp. 113-120
[6.]
J.L. Reverter, M. Sentí, J. Rubiés-Prat, A. Lucas, I. Salinas, E. Pizarro, et al.
Relationship between lipoprotein profile and urinary albumin excretion in type II diabetic patients with stable metabolic control.
Diabetes Care, 17 (1994), pp. 189-194
[7.]
M. Boemi, C. Sirolla, P. Fumelli, R.W. James.
Renal disease as a determinant of increased lipoprotein(a) concentrations in diabetic patients.
Diabetes Care, 22 (1999), pp. 2033-2036
[8.]
S.D. Sibley, J.E. Hokanson, M.W. Steffes, J.Q. Purnell, S.M. Marcovina, P.A. Cleary, et al.
Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.
Diabetes Care, 22 (1999), pp. 1165-1170
[9.]
J. Rubiés-Prat.
Manejo de la dislipemia en el paciente diabético.
Enfermedades cardiovasculares. Nutrición, genética y epidemiología, pp. 95-106
[10.]
A. Pérez, A.M. Wägner, G. Carreras, G. Giménez, J.L. Sánchez-Quesada, M. Rigla, et al.
Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus. Effect of glycemic control.
Diabetes Care, 160 (2000), pp. 2756-2762
[11.]
P. González Santos, T. González Alegre.
La diabetes mellitus, una situación de riesgo cardiovascular muy especial. Mecanismos aterogénicos e implicaciones terapéuticas.
Clin Invest Arterioscler, 13 (2001), pp. 62-67
[12.]
A.A. Parulkar, M.L. Pendergrass, R. Granda-Ayala, T.R. Lee, V.A. Fonseca.
Nonhypoglycemic effects of thiazolidinediones.
Ann Intern Med, 134 (2001), pp. 61-71
[13.]
American Diabetes Association. Management of dyslipidemia in adults with diabetes.
Diabetes Care, 25 (2002), pp. 74-77
[14.]
F. Pazos, J.J. Álvarez, J. Rubiés-Prat, C. Varela, M.A. Lasunción.
Long term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins.
J Clin Endocrinol Metab, 80 (1995), pp. 562-566
[15.]
D.C. Bauer, B. Ettinger, W.S. Browner.
Thyroid function and serum lipids in older women: a population-based study.
Am J Med, 104 (1998), pp. 546-551
[16.]
A.E. Hak, H.A.P. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C.M. Witteman.
Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women. The Rotterdam Study.
Ann Intern Med, 132 (2000), pp. 270-278
[17.]
D.S. Cooper.
Subclinical hypothyroidism.
N Engl J Med, 345 (2001), pp. 260-265
[18.]
J. Pedro-Botet, M. Sentí, J. Rubiés-Prat, A. Pelegrí, R. Romero.
When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines.
Nephrol Dial Transplant, 11 (1996), pp. 308-313
[19.]
C. Wanner.
Importance of hyperlipidaemia and therapy in renal patients.
Nephrol Dial Transplant, 15 (2000), pp. 92-96
[20.]
J.E. Rossouw.
Early risk of cardiovascular events after commencing hormone replecement therapy.
Curr Opin Lipidol, 12 (2001), pp. 371-375
[21.]
R.H. Grimm, J.M. Flack, G.A. Grandits, P.J. Elmer, J.D. Neaton, J.A. Cutler, et al.
Long-term effects on plasma lipids of diet and drugs to treat hypertension.
JAMA, 275 (1996), pp. 1549-1556
[22.]
P.J. Savage, S.L. Pressel, J.D. Curb, E.B. Schron, W.B. Applegate, H.R. Black, et al.
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. The Systolic Hypertension in the Elderly Program.
Arch Intern Med, 158 (1998), pp. 741-751
[23.]
B.A. Golomb, M.H. Criqui.
Antihypertensives. Much ado about lipids.
Arch Intern Med, 159 (1999), pp. 535-537
[24.]
M.R. Lakshman, D.J. Reda, B.J. Materson, W.C. Cushman, E.D. Freis.
Diuretics and ß-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension.
Arch Intern Med, 159 (1999), pp. 551-558
[25.]
T.W. Gress, F.J. Nieto, E. Shahar, M.R. Woffoord, F.L. Brancati.
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.
N Engl J Med, 342 (2000), pp. 905-912
[26.]
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[27.]
M.P. Dubé, D. Sprecher, W.K. Henry, J.A. Aberg, F.J. Torriani, H.N. Hodis, et al.
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Clin Infect Dis, 31 (2000), pp. 1216-1224
[29.]
S.R. Penzak, S.K. Chuck.
Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
Scand J Infect Dis, 32 (2000), pp. 111-123
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.